INT124247

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 2005
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 12
Total Number 14
Disease Relevance 3.87
Pain Relevance 1.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Snca) mitochondrion (Snca) histone binding (Snca)
plasma membrane (Snca) cytoskeleton (Snca) nucleus (Snca)
Anatomy Link Frequency
brain 4
glial cell 2
Murphy 2
cortex 2
hippocampus 2
Snca (Mus musculus)
Pain Link Frequency Relevance Heat
Hippocampus 189 99.04 Very High Very High Very High
Inflammation 13 96.64 Very High Very High Very High
Dopamine 47 89.40 High High
Catecholamine 2 88.44 High High
Inflammatory response 3 86.60 High High
Serotonin 9 71.52 Quite High
Substantia nigra 97 68.24 Quite High
Pain threshold 1 54.48 Quite High
monoamine 1 28.24 Quite Low
imagery 21 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Toxicity 40 99.12 Very High Very High Very High
Parkinson's Disease 142 98.44 Very High Very High Very High
Sprains And Strains 5 97.96 Very High Very High Very High
INFLAMMATION 16 96.64 Very High Very High Very High
Disease 361 96.48 Very High Very High Very High
Dementia 28 89.64 High High
Anxiety Disorder 8 87.76 High High
Stress 53 82.32 Quite High
Death 14 80.40 Quite High
Alzheimer's Dementia 18 76.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Additionally, the SNCA-specific siRNA reduced SNCA expression when compared to luciferase-siRNA (p = 0.004) and PBS (p = 0.036) treated control mice (Figure 1).
Negative_regulation (reduced) of Gene_expression (expression) of SNCA
1) Confidence 0.59 Published 2008 Journal Mol Neurodegener Section Body Doc Link PMC2612658 Disease Relevance 0 Pain Relevance 0.13
Although SNCA expression was significantly reduced in the SNCA siRNA treated hippocampi, we hypothesized that the efficacy of the siRNA in the brain might be underestimated due to partial diffusion of the siRNA into the contralateral hippocampus.
Negative_regulation (reduced) of Gene_expression (expression) of SNCA in brain associated with hippocampus
2) Confidence 0.59 Published 2008 Journal Mol Neurodegener Section Body Doc Link PMC2612658 Disease Relevance 0 Pain Relevance 0.14
In order to test the ability of naked siRNA to reduce SNCA expression in vivo, we identified the hippocampus and the cortex as having the highest expression of SNCA in the murine brain (data not shown).
Negative_regulation (reduce) of Gene_expression (expression) of SNCA in brain associated with hippocampus
3) Confidence 0.59 Published 2008 Journal Mol Neurodegener Section Body Doc Link PMC2612658 Disease Relevance 0 Pain Relevance 0.09
Quantitative RT-PCR analysis demonstrated that SNCA expression was significantly decreased in the right (treated) hippocampus of animals which have received SNCA siRNA when compared to the left (untreated) hippocampus (p = 0.037) as demonstrated by the R:L ratio of SNCA expression.
Negative_regulation (decreased) of Gene_expression (expression) of SNCA in hippocampus associated with hippocampus
4) Confidence 0.59 Published 2008 Journal Mol Neurodegener Section Body Doc Link PMC2612658 Disease Relevance 0 Pain Relevance 0.15
Hence therapy aimed at reducing SNCA expression levels may provide therapeutic benefit for patients with either familial or idiopathic PD.
Negative_regulation (reducing) of Gene_expression (expression) of SNCA associated with disease
5) Confidence 0.43 Published 2008 Journal Mol Neurodegener Section Body Doc Link PMC2612658 Disease Relevance 0.99 Pain Relevance 0.07
Additionally, the SNCA-specific siRNA reduced SNCA expression when compared to luciferase-siRNA (p = 0.004) and PBS (p = 0.036) treated control mice (Figure 1).
Negative_regulation (reduced) of Gene_expression (expression) of SNCA
6) Confidence 0.43 Published 2008 Journal Mol Neurodegener Section Body Doc Link PMC2612658 Disease Relevance 0 Pain Relevance 0.13
Utilizing a mouse SNCA specific probe, we determined if the knockdown of SNCA expression extended beyond the CA1 cannulation site (Figure 2).
Negative_regulation (knockdown) of Gene_expression (expression) of SNCA
7) Confidence 0.43 Published 2008 Journal Mol Neurodegener Section Body Doc Link PMC2612658 Disease Relevance 0.08 Pain Relevance 0.19
SNCA levels in the right CA1 (Figure 3A), the site of injection, remained noticeably reduced when compared to the uninjected control side through three weeks post-infusion.
Negative_regulation (reduced) of Gene_expression (levels) of SNCA
8) Confidence 0.38 Published 2008 Journal Mol Neurodegener Section Body Doc Link PMC2612658 Disease Relevance 0.08 Pain Relevance 0.10
Following in situ for SNCA, we observed approximately 60% knockdown in SNCA expression in the right CA1 and cortex compared to the uninjected left side (Figure 3) which replicated our previous experiments.
Negative_regulation (knockdown) of Gene_expression (expression) of SNCA in cortex
9) Confidence 0.37 Published 2008 Journal Mol Neurodegener Section Body Doc Link PMC2612658 Disease Relevance 0 Pain Relevance 0.03
Therefore, the reduction of SNCA expression and inhibition of NF?
Negative_regulation (reduction) of Gene_expression (expression) of SNCA
10) Confidence 0.37 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2925900 Disease Relevance 0.61 Pain Relevance 0.09
B; further studies to isolate the glial population in order to determine the glial cell SNCA load and level of NF?
Spec (determine) Negative_regulation (determine) of Spec (determine) Gene_expression (load) of SNCA in glial cell
11) Confidence 0.37 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2925900 Disease Relevance 0.60 Pain Relevance 0.08
However, it is worth noting that the protection by NAC in SNCA overexpressing mice against loss of TH+ terminals remains significant even after a conservative Bonferroni correction for multiple comparisons (3 measures of striatal dopaminergic innervation: percentage of area covered by TH+ terminals, percentage of area covered by DAT+ terminals, and striatal dopamine).
Negative_regulation (loss) of Gene_expression (protection) of SNCA associated with dopamine
12) Confidence 0.37 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2925900 Disease Relevance 0.19 Pain Relevance 0.04
We tested for a causal relationship between the two findings by employing B6N (expressing alpha-synuclein), B6JOla (not expressing alpha-syn) and the third strain C57BL/6JCrl (B6Jax, expressing alpha-syn).
Negative_regulation (employing) of Gene_expression (expressing) of alpha-synuclein associated with sprains and strains
13) Confidence 0.29 Published 2005 Journal Behav. Brain Res. Section Abstract Doc Link 15639180 Disease Relevance 0.83 Pain Relevance 0.05
Concerning to vesicle formation, Murphy et al. (2000), reported that alpha-synuclein may regulate the size of synaptic vesicles in mature neurons by observing a significant reduction in distal synaptic vesicles pool formation when the expression of alpha-synuclein is suppressed by antisense oligonucleotide technology (Murphy et al., 2000).
Negative_regulation (suppressed) of Gene_expression (expression) of alpha-synuclein in Murphy
14) Confidence 0.23 Published 2010 Journal Frontiers in Aging Neuroscience Section Body Doc Link PMC2890153 Disease Relevance 0.49 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox